Filters

New Line of Cancer Antibodies

411 products

Showing 25 - 48 of 411 products
View
Western blot of human A431 cells treated with Calyculin A (100 nM) for 30 min. Blot lanes were untreated (lanes 1, 3, & 5) or treated with lambda phosphatase (lanes 2, 4, & 6) then probed with anti-ATM (Ser-794) (lanes 1 & 2), anti-ATM (C-Terminal) (lanes 3 & 4), or anti-ATM (Ser-1981) (lanes 5 & 6).Immunocytochemical labeling of ATM phosphorylation in control (Top row) or calyculin A-treated A431 cells (Bottom row). The cells were labeled with mouse monoclonal ATM (C-terminal region) (AM3611) and ATM (Ser-1981) (AM3661). The antibodies were detected using goat anti-mouse-DyLight® 594.
Western blot image of human recombinant Atrogin 1 (lanes 1-6). The blot was probed with rabbit polyclonal Atrogin-1 (lanes 1-3) and rat monoclonal Atrogin-1 (lanes 4-6) at 1:1000 (lanes 1 & 4), 1:2000 (lanes 2 & 5), and 1:4000 (lanes 3 & 6).
Western blot image of mouse gastrocnemius (lanes 1 & 3) and mouse diaphragm tissue lysate (lanes 2 & 4). The blot was probed with anti-Atrogin-1 (AP2041; lanes 1-4) in the presence (lanes 3 & 4) or absence (lanes 1 & 2) of Atrogin-1 peptide (AX2045).Formalin fixed, citric acid treated paraffin sections of E16 mouse skeletal muscle. Sections were probed with anti-Atrogin-1 (AP2041) then anti-Rabbit:HRP before detection using DAB. (Images provided by Carl Hobbs and Dr. Pat Doherty at Wolfson Centre for Age-Related Diseases, King's College London).
Western blot of human Jurkat cells treated with calyculin A (100 nM) for 30 min. The blots were untreated (lanes 1 & 3) or treated (lanes 2 & 4) with lambda phosphatase and probed with anti-B-Raf (N-terminus) (lanes 1 & 2) or anti-B-Raf (Ser-446) (lanes 3 & 4).
Western blot of 293 cells mock transfected (lane 1) or transiently transfected with pLenti6/TR lentiviral vector (lanes 2 & 3). Blots were probed with anti-Bsd (lanes 1-3). Molecular weight (MW) standards show that Bsd is expressed as a 13 kDa band in only the transfected cells.Immunocytochemical labeling of Blasticidin S Deaminase (Bsd) in 293 cells mock transfected (left) and transiently transfected with pLenti6/TR lentiviral vector (right). The cells were labeled with anti-Bsd (BP1231) and detected using appropriate secondary antibody conjugated to Texas Red. (Images provided by Charles Mashburn and Dr. George Smith at the University of Kentucky, Spinal Cord and Brain Injury Research Center).
Western blot analysis of K-562 cells treated with pervanadate (1 mM) for 30 minutes (lanes 1, 3, & 5). Some lanes were treated with alkaline phosphatase to remove phosphorylation on c-Abl (lanes 2, 4, & 6), then the blots were probed with anti-c-Abl (lanes 1 & 2), anti-c-Abl (Tyr-412) (AP1271; lanes 3 & 4), or anti-c-Abl (Tyr-245) (AP1251; lanes 5 & 6).
Western blot analysis of human Jurkat cells untreated (lanes 1 & 3) or treated with pervanadate (1 mM) for 30 minutes (lanes 2 & 4). The blot was probed with anti-c-Cbl (CM1591; lanes 1 & 2) or anti-c-Cbl (Tyr-700) (CM1611; lanes 3 & 4).
Western blot. Left Lane -- Cultured normal mouse embryo fibroblasts were transfected with a plasmid containing the SAP1a cDNA fused with a c-myc epitope tag at its C-terminus. Lane 1, 30 µg protein; lane 2, 20 µg protein; lane 3, 10 µg protein; lane 4, 5 µg protein.
Western blot of GST fusion protein containing human C-Raf. The blot was probed with polyclonal anti-C-Raf (C-terminus) antibody in the presence (lanes 2-4) or absence (lane 1) of C-Raf (C-terminus) blocking peptide (lane 2), C-Raf (Ser-471) peptide (lane 3), or unrelated peptide (lane 4).
Western blot of human A431 (lane 1) and Jurkat (lane 2) cells probed with mouse monoclonal anti-C-Raf (N-terminal) antibody at 1:500.
Western blot analysis of mouse SYF cells transformed with c-Src then left untreated (lanes 1, 3, & 5) or treated with pervanadate (1 mM) for 30 minutes (lanes 2, 4, & 6). The blot was probed with anti-c-Src (Tyr-215) (lanes 1 & 2), anti-c-Src (N-terminal region) (lanes 3 & 4), and anti-c-Src (Tyr-530) (lanes 5 & 6).

Recently Viewed